



**B**

Treatment	<i>n</i>	Median survival (days)	p-value
IT AAV9.trastuzumab + PBS	11	92	<0.0001
IT AAV9.trastuzumab + clodronate	6	70.5	0.0117
No treatment + PBS	9	50	-
No treatment + clodronate	11	48	0.8462



**Supplemental Figure 9. IT AAV9.trastuzumab tumor prophylaxis in the setting of continuous systemic macrophage depletion.** (A) Kaplan-Meier survival curves for mice that received IT AAV9.trastuzumab tumor prophylaxis or IT AAV9.2.10AmAb control treatment with or without systemic macrophage depletion. (B) Tabulated survival and statistical data for Fig. 6A. (C) IgG transgene expression in brain tissue measured by protein A ELISA of brain homogenate and graphed as a percent of total protein in brain homogenate. (D) CD68 IHC staining of formalin-fixed paraffin-embedded spleens harvested at necropsy from animals treated with liposomal PBS or liposomal clodronate.